MedPage Today on MSN1d
Avoidable Cancers After Colonoscopy; Real-World Rinvoq Data; Drug Flops in IBS TrialResearchers in Gastroenterology evaluated strategies for preventing avoidable colorectal cancers after colonoscopy. In ...
The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...
JAK inhibitor Rinvoq (upadacitinib) has been backed by the CHMP as a 15mg, once-daily treatment for adults with GCA, an ...
Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
A key regulatory win could turn this under-the-radar treatment into AbbVie's next billion-dollar success story.
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...
Zacks.com on MSN8d
Here's How to Play AbbVie Stock as it Enters the Obesity SpaceThey focus on the company’s fundamentals to understand how to play the stock. ABBV’s Successful New Drugs — Skyrizi and Rinvoq AbbVie lost patent protection for Humira in the United States in January ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback